Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:

Abstract: A display panel, a manufacturing method thereof, and a display device are provided. The display panel includes a driving backplate, functional component groups, and micro-LED chips. The functional component groups are integrated in regions where the micro-LED chips are not disposed and are multiplexed as alignment marks. In a mass transfer process of the micro-LED chips, the alignment marks are prevented from additionally occupying pixel space by using part of functional components multiplexed as the alignment marks under a precondition of ensuring alignment accuracy.

Abstract: A display panel and a display device are provided. The display panel includes a first pixel area and a second pixel area adjacent to the first pixel area. The display panel includes an array substrate, a color film substrate arranged oppositely to the array substrate, a liquid crystal layer between the array substrate and the color film substrate, and a backlight module positioned at a side of the color film substrate, which is back on to the array substrate. The display panel comprises a plurality of micro light emitting diode (micro LED) lighting units. A transparent area is placed among the micro LED lighting units, and the color film substrate includes a color filter in the second pixel area.

Abstract: The present invention provides a fingerprint identification method, an electronic device and a display panel. The method includes: acquiring a center position information of a geometric center position of the touch operation getting a touch information of the touch operation; determining whether the center position information is the same as the geometric center position of one of the fingerprint identification arrays; getting a fingerprint image data according to a judgment result and the touch information; and unlocking the screen when the fingerprint image data is consistent with a preset fingerprint data.

Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:

Abstract: A writing implement, including a pen tube, a guiding element, a motion sensor, and a controller. An end portion of the pen tube is provided with a nib. The guiding element and the motion sensor are disposed on the pen tube, and the guiding element is controlled by the controller. In the process of writing, the motion sensor detects words and pencraft characteristics when a user holds the pen tube for writing, and the controller controls the guiding element to generate a guiding force to guide the words and pencraft characteristics when writing, to approach or be equal to words and pencraft characteristics prepared to be written. Therefore, the present invention may train a user to copy the handwriting of a master or actively guide the user to wield the pen by means of the writing implement.

Abstract: Disclosed are next-generation multi-mutated capside protein-modified rAAV expression vector, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vector, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.

Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: An underwater propulsion apparatus includes a motor and a control system for controlling the motor. The control system includes a remote controller and a motor driving device, wirelessly communicating with the remote controller. The motor driving device includes a communication repeater module and a motor driving module. The communication repeater module is configured for detecting interruptions or non-receipt of a wireless signal transmitted by the remote controller. Wireless signals to the motor driving module are transmitted by the remote controller to the communication repeater module. The motor driving module is configured for receiving the wireless signal, and outputs a driving signal for driving the motor according to the wireless signal, the motor driving module shutting down when no signal is received.

Abstract: Method for fabricating A packaging structure is provided. The packaging structure includes a base substrate including a solder pad body region and a trench region adjacent to and around the solder pad body region. The packaging structure includes a passivation layer on the base substrate and exposing the solder pad body region and the trench region. The packaging structure includes a main body solder pad on the solder pad body region of the base substrate, and one or more trenches on the trench region of the base substrate and between the passivation layer and the main body solder pad. The packaging structure includes a bonding conductive wire having one end connected to the main body solder pad.

Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.

Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.

Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.

Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:

Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.